Announcements

OICR's Board of Directors has approved funding of the Personalized Medicine Research Fund competition held in November 2010. The following table provides listings of grants with funding amounts. The funding amount includes eligible institutional overhead costs.

Thank you to all the applicants who submitted an application to the Personalized Medicine Research Fund competition. The panel feedback and critique will be mailed out to all successful and unsuccessful applicants in the next two weeks.

OICR congratulates the successful applicants and wishes all applicants success in their research endeavours.

PERSONALIZED MEDICINE RESEARCH FUND – ROUND I COMPETITION 2011-12

Investigator

Institution

Project title

Budget

Period (years)

Rob Bristow

UHN

Augmin-Centrosome Complexes: A Novel Marker for Prostate Cancer Aggression/Progression

$651,685

3

Bharati Bapat

Samuel Lunenfeld Research Institute

Analysis of novel methylation biomarkers distinguishing aggressive from indolent prostate cancer

$619,440

3

Aaron Schimmer

Ontario Cancer Institute

Toll-like receptor activation as a therapeutic strategy for the treatment of leukemia

$458,280

2

Fei-Fei Liu

UHN

Micro-RNA and mRNA Expression Profiling to Predict Outcome and Characterize the Cervix Cancer Microenvironment

$634,407

3

Eleftherios Diamandis

Mount Sinai Hospital

An Integrated Proteomic Approach to Novel Pancreatic Cancer Biomarker Discovery

$476,184

3

Peeyush Lala

UWO

COX-2 mediated induction of stem cell phenotype in human breast cancer and identification of therapeutic targets

$602,787

3

Laura Curiel

Thunder Bay Regional Research Institute

Antibody-labeled Magnetic Resonance Guidance for Non Invasive Localized Prostate Cancer Treatment

$282,151

3

Geoffrey Liu

UHN

Pharmacogenetic Study of Gemcitabine in Pancreatic Cancer: Analysis of Clinical and Observational Trials

$303,812

2

Aaron Schimmer

OCI

A phase I clinical trial of a mitochondrial protein synthesis inhibitor in patients with relapsed or refractory AML

$638,820

3

Vuk Stambolic

UHN

Identification of predictive biomarkers of metformin benefit in women with early stage breast cancer enrolled in MA.32, a  phase III trial of the effect of metformin on recurrence and survival in early stage of breast cancer

$694,440

3

Grand Total

$5,362,006